Fibrin degradation products and survival in patients with chronic obstructive pulmonary disease: a protocolized prospective observational study.
All-cause mortality
Biomarker
COPD
Cohort
D-dimer
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
27 Jun 2023
27 Jun 2023
Historique:
received:
24
03
2023
accepted:
08
06
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
27
6
2023
Statut:
epublish
Résumé
Patients with chronic obstructive pulmonary disease (COPD) have a high incidence of cardiovascular disease including thromboembolisms. Fibrin degradation products, like D-dimer, have been associated with death from all causes in healthy individuals and COPD patients. We aimed to determine the (i) association between D-dimer levels and all-cause mortality and time being alive and out of a hospital, (ii) possible modifying effect of anticoagulant treatment,, and (iii) distribution of D-dimer in patients with moderate to severe COPD. Results of routinely measured stable phase D-dimer samples from COPD-outpatients at Copenhagen University Hospital - Herlev and Gentofte, COPD-outpatient clinic were collected using the Danish registries. These were used to examine whether COPD-patients with a D-dimer level in the upper quartile, had a higher risk of death from all causes within 365 days. In the unadjusted Cox proportional hazards regression we found an association between high D-dimer and all-cause mortality: Hazard ratio (HR): 2.3 (95% Confidence Interval (CI) 1.1-4.7). In the fully adjusted regression, the HR was 1.8 (CI 0.8-3.9). We did not find any interaction between D-dimer and anticoagulant or antiplatelet therapy. For the secondary outcome, proportion of days alive and out of hospital in 365 days (pDAOH), the unadjusted multiple linear regression had an association between high D-dimer level and pDAOH: -2.7% points (pp) (CI -3.9 pp - -1.5 pp), which was attenuated to -1,7pp (-2.9pp - -0.4pp) in the fully adjusted regression. In patients with moderate to severe COPD, patients with a high level of D-dimer were more likely to die; however, the signal was not strong in the adjusted analyses and our results do not support unselected risk stratification with D-dimer in COPD-outpatients.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with chronic obstructive pulmonary disease (COPD) have a high incidence of cardiovascular disease including thromboembolisms. Fibrin degradation products, like D-dimer, have been associated with death from all causes in healthy individuals and COPD patients. We aimed to determine the (i) association between D-dimer levels and all-cause mortality and time being alive and out of a hospital, (ii) possible modifying effect of anticoagulant treatment,, and (iii) distribution of D-dimer in patients with moderate to severe COPD.
METHODS
METHODS
Results of routinely measured stable phase D-dimer samples from COPD-outpatients at Copenhagen University Hospital - Herlev and Gentofte, COPD-outpatient clinic were collected using the Danish registries. These were used to examine whether COPD-patients with a D-dimer level in the upper quartile, had a higher risk of death from all causes within 365 days.
RESULTS
RESULTS
In the unadjusted Cox proportional hazards regression we found an association between high D-dimer and all-cause mortality: Hazard ratio (HR): 2.3 (95% Confidence Interval (CI) 1.1-4.7). In the fully adjusted regression, the HR was 1.8 (CI 0.8-3.9). We did not find any interaction between D-dimer and anticoagulant or antiplatelet therapy. For the secondary outcome, proportion of days alive and out of hospital in 365 days (pDAOH), the unadjusted multiple linear regression had an association between high D-dimer level and pDAOH: -2.7% points (pp) (CI -3.9 pp - -1.5 pp), which was attenuated to -1,7pp (-2.9pp - -0.4pp) in the fully adjusted regression.
CONCLUSIONS
CONCLUSIONS
In patients with moderate to severe COPD, patients with a high level of D-dimer were more likely to die; however, the signal was not strong in the adjusted analyses and our results do not support unselected risk stratification with D-dimer in COPD-outpatients.
Identifiants
pubmed: 37370121
doi: 10.1186/s12931-023-02472-9
pii: 10.1186/s12931-023-02472-9
pmc: PMC10294503
doi:
Substances chimiques
Fibrin Fibrinogen Degradation Products
0
Anticoagulants
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
172Informations de copyright
© 2023. The Author(s).
Références
COPD. 2012 Aug;9(4):426-31
pubmed: 22612665
Haematologica. 2013 Sep;98(9):1476-80
pubmed: 23645692
PLoS One. 2021 Sep 2;16(9):e0256480
pubmed: 34473738
Eur Respir J. 2016 Feb;47(2):473-81
pubmed: 26585434
Respiration. 2006;73(4):428-33
pubmed: 16636527
Int J Epidemiol. 2017 Jun 1;46(3):798-798f
pubmed: 27789670
Clin Chim Acta. 2016 Apr 1;455:55-9
pubmed: 26826394
Respirology. 2021 Apr;26(4):342-351
pubmed: 33164314
Chest. 2013 Oct;144(4):1163-1178
pubmed: 23722528
Eur Rev Med Pharmacol Sci. 2021 Mar;25(6):2604-2616
pubmed: 33829447
Clin Epidemiol. 2020 May 18;12:469-475
pubmed: 32547238
Thromb Res. 2011 Oct;128(4):e24-8
pubmed: 21624643
J Biol Regul Homeost Agents. 2016 Jul-Sep;30(3):839-845
pubmed: 27655508
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Lancet. 2018 Nov 10;392(10159):2052-2090
pubmed: 30340847
ERJ Open Res. 2021 Nov 01;7(4):
pubmed: 34729369
Thromb Haemost. 1994 Sep;72(3):343-6
pubmed: 7855781
Diagnostics (Basel). 2021 Aug 10;11(8):
pubmed: 34441381
Am J Hematol. 2009 Jun;84(6):349-53
pubmed: 19472201
Int J Chron Obstruct Pulmon Dis. 2016 Oct 31;11:2729-2736
pubmed: 27843309
Eur Respir J. 2010 Jun;35(6):1243-8
pubmed: 19926740
Malawi Med J. 2021 Dec;33(4):276-280
pubmed: 35291388
Am J Med Sci. 2015 Jan;349(1):29-35
pubmed: 25233043
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Eur J Epidemiol. 2014 Aug;29(8):541-9
pubmed: 24965263